Growth hormone intrauterine perfusion combined with replacement cycle in the treatment of non-response thin endometrium: report of 5 cases

To investigate the effects of the frozen embryo transplantation for patients with poor outcome of endometrial growth by using growth hormone intrauterine perfusion combined with replacement cycle in the treatment of non-response thin endometrium. This is a prospective study and study participants were consecutively recruited between Jun 2014 and December 2014. A total of 5 non-response thin endometrium patients were selected, with treatment by frozen thawed embryo transfer from the Reproductive Center of Hunan Provincial Maternal and Child Health Hospital. The mean endometrial thickness of 5 patients on progesterone day was 7.96 ± 0.71 mm, more than the mean endometrial thickness of the first perfusion (5.78 ± 0.65) mm, the difference was statistically significant (t=10.46, P<0.05). All endometrial thickness on transplantation day was more than 7 mm. The average concentration of E2 was 9387.8 + 2623.87 pmol/l on the progesterone day. Clinical pregnancy and implantation rate of all cases was 72.73% (8/11), including 2 patients with full-term delivery and 1 patient with continued pregnancy; Embryo development of 1 patient diapause due to incision pregnancy, abortion embryo genetic testing results indicated normality. GH uterine cavity perfusion was a useful method for treatment of nonreactivity thin endometrium, and was helpful for improvement of endometrial thickness and receptivity, improve embryo implantation environment by assistance for HRT under the high estrogen levels.